1.Professor BU He's Experience in Integrative Internal and External Treatment of Pediatric Functional Constipation
Zixuan WANG ; Xiaoyi GUO ; Yuting ZHANG
Journal of Traditional Chinese Medicine 2025;66(15):1534-1537
This paper summarized Professor BU He's clinical experience in the integrative internal and external treatment of pediatric functional constipation. He believes that dysfunction of the spleen in transportation leads to impaired function of the sanjiao (三焦) and intestinal obstruction, which constitutes the core pathogenesis of pediatric functional constipation. The treatment emphasizes regulating the spleen and harmonizing the pivot, as well as unblocking the bowel and eliminating stagnation. An integrated approach combining internal and external therapies is advocated. Internally, Chinese herbal medicine, primarily Modified Sijunzi Decoction and Shaoyao Gancao Decoction (四君子汤合芍药甘草汤加减) is used to regulate the internal organs. Externally, pediatric tuina and moxibustion on qi interlocking are employed. Together, these methods fortify the spleen and facilitate transportation, restoring the smooth function of the sanjiao pivot, and ensuring intestinal patency, thereby relieving constipation.
2.Zuoguiwan Regulates Pdx1 Pathway to Improve Pancreas Development in Offspring of Gestational Diabetes Mellitus Model Rats
Wanqiu LIANG ; Rang CHEN ; Le ZHAO ; Xiaoyi REN ; Qianhui SU ; Yonghui WANG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(18):10-19
ObjectiveTo explore the mechanism by which Zuoguiwan improves the pancreas development in the gestational diabetes mellitus (GDM) model by observing the effects of Zuoguiwan on the expression of key regulatory factors in different stages of pancreas development. MethodsPregnant Wistar rats were randomly assigned into blank, model, insulin detemir (20 U·kg-1) and Zuoguiwan (1.89 g·kg-1) groups (n=18). GDM was induced by peritoneal injection of streptozotocin on day 6.5 (E6.5d) in the embryonic stage, and the blank group was given an equal volume of sodium citrate buffer. The modeling performance was assessed by measuring the blood glucose of pregnant rats. Except the blank group and model group, pregnant rats in other groups were administrated with corresponding drugs from E9.5d to delivery. The random blood glucose of pregnant rats was monitored, and the embryos and offspring rats were measured for the length and weighed on E12.5d, E18.5d and day 21 after birth (B21d). The Lee's index of rats on B21d was calculated. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the fasting insulin (FINS) levels of B22d rats and the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) was calculated. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), total cholesterol (CHO), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) in E18.5d pregnant rats and B22d offspring were determined. The pathological changes in the pancreas of E12.5d, E18.5d and B22d rats were observed by hematoxylin-eosin (HE) staining. Western blot was used to determine the protein levels of pancreatic duodenal homeobox 1 (Pdx1), pancreas-specific transcription factor 1a (Ptf1a), and sex-determining region Y-box protein 9 (Sox9) in the pancreas of E12.5d embryos, Pdx1, Nkx2 homeobox 2 (Nkx2.2), and hairy and enhancer of split-1 (Hes1) in the pancreas of E18.5d embryos, and Pdx1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa), and NK transcription factor-related homeobox gene family 6 locus 1 (Nkx6.1) in the pancreas of B22d rats. ResultsCompared with the blank group, the model group showed elevated blood glucose levels in pregnant rats on B0d, E9.5d, E12.5d, E15.5d, and E18.5d (P<0.05, P<0.01), decreased body weight and body length (P<0.01) and increased Lee's index in the offspring. In addition, the B22d offspring showed rising levels of FBG, FINS, HOMA-IR, AST, and TG (P<0.01), a declined level of HDL (P<0.01), and pancreatic acinous cells with edema and loose arrangement. The pregnant rats on E18.5d exhibited raised levels of ALT, AST, and TG (P<0.05, P<0.01) in the pancreas and a declined level of HDL (P<0.05). The E12.5d embryos showed up-regulated protein levels of Pdx1, Sox9, and Ptf1a in the pancreas (P<0.01) and the E18.5d embryos exhibited down-regulated protein levels of Pdx1, Nkx2.2, and Hes1 in the pancreas (P<0.01). The protein levels of Pdx1, Nkx6.1, and Mafa in the pancreas of B22d offspring were down-regulated (P<0.01). Compared with the model group, the insulin group exhibited lowered blood glucose in pregnant rats on B0d, E15.5d, and E18.5d (P<0.05, P<0.01). The offspring in all treatment groups showcased increased body weight and body length (P<0.01) and decreased Lee's index. The B22d offspring exhibited declined levels of FBG, FINS, and HOMA-IR in the insulin group (P<0.01) and lowered levels of FBG and HOMA-IR in the Zuoguiwan group (P<0.01). The B22d offspring in all the treatment groups showed reduced levels of ALT, AST, TBIL, CHO, TG, and LDL, a raised level of HDL, and alleviated edema of pancreatic acinous cells. The pregnant rats on E18.5d demonstrated declined levels of TG and ALT (P<0.05, P<0.01) and an elevated level of HDL (P<0.05). The pancreas of E12.5d embryos presented down-regulated protein levels of Pdx1 and Sox9 and an up-regulated protein level of Ptf1a in the insulin group (P<0.05). The pancreas of E12.5d embryos in the Zuoguiwan group presented down-regulated protein levels of Pdx1, Sox9, and Ptf1a (P<0.01). All the treatment groups showed up-regulated protein levels of Pdx1, Nkx2.2, and Hes1 in the pancreas of E18.5d embryos (P<0.01) and Pdx1, Nkx6.1, and Mafa in the pancreas of B22d embryos (P<0.05, P<0.01). ConclusionZuoguiwan can promote the growth and development and ameliorate the pathological changes in the pancreas of the offspring of GDM model by regulating the expression of Pdx1 pathway-related regulatory factors in different stages of pancreas development.
3.Evidence gap between the systematic reviews and clinical concerns in acupuncture and moxibustion for frozen shoulder.
Zhen LUO ; Weijuan GANG ; Xiaoyi HU ; Huan CHEN ; Lu WANG ; Wencui XIU ; Tianyu MING ; Xianghong JING
Chinese Acupuncture & Moxibustion 2025;45(11):1673-1680
OBJECTIVE:
To reveal the gap between the evidence of systematic reviews (SRs) and clinical concerns by systematically summarizing the evidence on acupuncture and moxibustion for frozen shoulder and investigating the concerns and needs of clinicians in treatment with acupuncture and moxibustion for this disease.
METHODS:
The articles of SR and Meta-analysis on acupuncture and moxibustion for frozen shoulder were searched from CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase and Cochrane Library, starting from the inception of each database up to December 31st, 2022. Two researchers screened the articles and extracted data independently. Using AMSTAR-2, the methodological quality of the included studies was evaluated. Based on systematic reviews and expert discussion, a questionnaire on clinical concerns of acupuncture and moxibustion for frozen shoulder was developed and distributed to clinicians. The discrepancies between the evidence and clinical concerns were compared from 5 dimensions, including population, interventions, control measures, outcome indicators and review time points.
RESULTS:
The evidence gaps existed between SRs and clinical concerns. In the existing studies, the needs of personalized treatment were not fully considered in terms of different syndromes/patterns of frozen shoulder and stages of illness, the outcome indicators were not employed properly, the time for outcome measurement was vague, the control groups were set up outside of standardization, and the methodological quality was lower.
CONCLUSION
It is suggested that future studies should improve the quality of methodology, lay more consideration to different patient groups, optimize outcome indicators and standardize the setting of control groups, so as to better meet the needs of patients and achieve the best match between evidence and clinicians' needs.
Humans
;
Acupuncture Therapy
;
Bursitis/therapy*
;
Evidence Gaps
;
Moxibustion
;
Systematic Reviews as Topic
;
Meta-Analysis as Topic
4.AI-integrated IQPD framework of quality prediction and diagnostics in small-sample multi-unit pharmaceutical manufacturing: Advancing from experience-driven to data-driven manufacturing.
Kaiyi WANG ; Xinhai CHEN ; Nan LI ; Huimin FENG ; Xiaoyi LIU ; Yifei WANG ; Yanfei WU ; Yufeng GUO ; Shuoshuo XU ; Lu YAO ; Zhaohua ZHANG ; Jun JIA ; Zhishu TANG ; Zhisheng WU
Acta Pharmaceutica Sinica B 2025;15(8):4193-4209
The pharmaceutical industry faces challenges in quality digitization for complex multi-stage processes, especially in small-sample systems. Here, an intelligent quality prediction and diagnostic (IQPD) framework was developed and applied to Tong Ren Tang's Niuhuang Qingxin Pills, utilizing four years of data collected from four production units, covering the entire process from raw materials to finished products. In this framework, a novel path-enhanced double ensemble quality prediction model (PeDGAT) is proposed, which combines a graph attention network and path information to encode inter-unit long-range and sequential dependencies. Additionally, the double ensemble strategy enhances model stability in small samples. Compared to global traditional models, PeDGAT achieves state-of-the-art results, with an average improvement of 13.18% and 87.67% in prediction accuracy and stability on three indicators. Additionally, a more in-depth diagnostic model leveraging grey correlation analysis and expert knowledge reduces reliance on large samples, offering a panoramic view of attribute relationships across units and improving process transparency. Finally, the IQPD framework integrates into a Human-Cyber-Physical system, enabling faster decision-making and real-time quality adjustments for Tong Ren Tang's Niuhuang Qingxin Pills, a product with annual sales exceeding 100 million CNY. This facilitates the transition from experience-driven to data-driven manufacturing.
5.Quercetin ameliorates myocardial injury in diabetic rats by regulating L-type calcium channels.
Hongyan SUN ; Guoqing LU ; Chengwen FU ; Mengwen XU ; Xiaoyi ZHU ; Guoquan XING ; Leqiang LIU ; Yufei KE ; Lemei CUI ; Ruiyang CHEN ; Lei WANG ; Pinfang KANG ; Bi TANG
Journal of Southern Medical University 2025;45(3):531-541
OBJECTIVES:
To investigate the effects of quercetin on cuproptosis and L-type calcium currents in the myocardium of diabetic rats.
METHODS:
Forty SD rats were randomized into control group and diabetic model groups. The rat models of diabetes mellitus (DM) induced by high-fat and high-sugar diet combined with streptozotocin (STZ) injection were further divided into DM model group, quercetin treatment group, and empagliflozin treatment group (n=10). Blood glucose and body weight were measured every other week, and cardiac function of the rats was evaluated using echocardiography. HE staining, Sirius red staining, and wheat germ agglutinin (WGA) analysis were used to observe the changes in myocardial histomorphology, and serum copper levels and myocardial FDX1 expression were detected. In cultured rat cardiomyocyte H9c2 cells with high-glucose exposure, the effects of quercetin and elesclomol, alone or in combination, on intracellular CK-MB and LDH levels and FDX1 expression were assessed, and the changes in L-type calcium currents were analyzed using patch-clamp technique.
RESULTS:
The diabetic rats exhibited elevated blood glucose, reduced body weight, impaired left ventricular function, increased serum copper levels and myocardial FDX1 expression, decreased L-type calcium currents, and prolonged action potential duration. Quercetin and empagliflozin treatment significantly lowered blood glucose, improved body weight, and restored cardiac function of the diabetic rats, and compared with empagliflozin, quercetin more effectively reduced serum copper levels, downregulated FDX1 expression, and enhanced myocardial L-type calcium currents in diabetic rats. In H9c2 cells, high glucose exposure significantly increased myocardial expressions of FDX1, CK-MB and LDH, which were effectively lowered by quercetin treatment; Elesclomol further elevated FDX1, CK-MB and LDH levels in the exposed cells, and these changes were not significantly affected by the application of quercetin.
CONCLUSIONS
Quercetin ameliorates myocardial injury in diabetic rats possibly by suppressing myocardial cuproptosis signaling and restoring L-type calcium channel activity.
Animals
;
Quercetin/pharmacology*
;
Calcium Channels, L-Type/metabolism*
;
Diabetes Mellitus, Experimental/metabolism*
;
Rats, Sprague-Dawley
;
Rats
;
Myocytes, Cardiac/drug effects*
;
Myocardium/pathology*
;
Male
6.Activation of Centromedial Amygdala GABAergic Neurons Produces Hypotension in Mice.
Xiaoyi WANG ; Ziteng YUE ; Luo SHI ; Wei HE ; Liuqi SHAO ; Yuhang LIU ; Jinye ZHANG ; Shangyu BI ; Tianjiao DENG ; Fang YUAN ; Sheng WANG
Neuroscience Bulletin 2025;41(5):759-774
The central amygdala (CeA) is a crucial modulator of emotional, behavioral, and autonomic functions, including cardiovascular responses. Despite its importance, the specific circuit by which the CeA modulates blood pressure remains insufficiently explored. Our investigations demonstrate that photostimulation of GABAergic neurons in the centromedial amygdala (CeMGABA), as opposed to those in the centrolateral amygdala (CeL), produces a depressor response in both anesthetized and freely-moving mice. In addition, activation of CeMGABA axonal terminals projecting to the nucleus tractus solitarius (NTS) significantly reduces blood pressure. These CeMGABA neurons form synaptic connections with NTS neurons, allowing for the modulation of cardiovascular responses by influencing the caudal or rostral ventrolateral medulla. Furthermore, CeMGABA neurons targeting the NTS receive dense inputs from the CeL. Consequently, stimulation of CeMGABA neurons elicits hypotension through the CeM-NTS circuit, offering deeper insights into the cardiovascular responses associated with emotions and behaviors.
Animals
;
GABAergic Neurons/physiology*
;
Male
;
Central Amygdaloid Nucleus/physiopathology*
;
Hypotension/physiopathology*
;
Mice
;
Blood Pressure/physiology*
;
Mice, Inbred C57BL
;
Solitary Nucleus/physiology*
;
Photic Stimulation
;
Neural Pathways/physiology*
7.Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.
Kai WANG ; Duanfang CAO ; Lanlan LIU ; Xiaoyi FAN ; Yihuan LIN ; Wenting HE ; Yunze ZHAI ; Pingyong XU ; Xiyun YAN ; Haikun WANG ; Xinzheng ZHANG ; Pengyuan YANG
Frontiers of Medicine 2025;19(3):493-506
Neutralizing antibodies have been designed to specifically target and bind to the receptor binding domain (RBD) of spike (S) protein to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from attaching to angiotensin converting enzyme 2 (ACE2). This study reports a distinctive nanobody, designated as VHH21, that directly catalyzes the S-trimer into an irreversible transition state through postfusion conformational changes. Derived from camels immunized with multiple antigens, a set of nanobodies with high affinity for the S1 protein displays abilities to neutralize pseudovirion infections with a broad resistance to variants of concern of SARS-CoV-2, including SARS-CoV and BatRaTG13. Importantly, a super-resolution screening and analysis platform based on visual fluorescence probes was designed and applied to monitor single proteins and protein subunits. A spontaneously occurring dimeric form of VHH21 was obtained to rapidly destroy the S-trimer. Structural analysis via cryogenic electron microscopy revealed that VHH21 targets specific conserved epitopes on the S protein, distinct from the ACE2 binding site on the RBD, which destabilizes the fusion process. This research highlights the potential of VHH21 as an abzyme-like nanobody (nanoabzyme) possessing broad-spectrum binding capabilities and highly effective anti-viral properties and offers a promising strategy for combating coronavirus outbreaks.
Single-Domain Antibodies/immunology*
;
Spike Glycoprotein, Coronavirus/metabolism*
;
SARS-CoV-2/immunology*
;
Animals
;
Humans
;
Antibodies, Neutralizing/immunology*
;
Camelus
;
COVID-19/immunology*
;
Antibodies, Viral/immunology*
;
Angiotensin-Converting Enzyme 2
8.Multi-center clinical study on the efficacy and safety of combined lienal polypeptide injection therapy in children with Mycoplasma pneumoniae pneumonia
Qi CHENG ; Yunxiao SHANG ; Han ZHANG ; Jiujun LI ; Ning CHEN ; Lishen SHAN ; Nan YANG ; Lihua NING ; Xuemei BAI ; Jianhua LIU ; Yuling HAN ; Jichun WANG ; Jing LI ; Yong FENG ; Liyun LIU ; Li CHEN ; Si LIU ; Qinzhen ZHANG ; Jia ZHENG ; Fengchao LI ; Sukun LU ; Yun ZHANG ; Xiaoyi CHAI
International Journal of Pediatrics 2025;52(3):204-210
Objective:To observe the efficacy and safety of combined lienal polypeptide injection therapy in the treatment of Mycoplasma pneumoniae pneumonia(MPP)in children aged 3 to 14 years old in multiple clinical centers.Methods:A randomized,controlled,multi-center clinical study design was adopted.A total of 240 hospitalized children aged 3 to 14 years old with MPP from 7 hospitals from September 1,2023 to January 31,2024 were included.According to the severity of pneumonia,they were divided into the mild MPP group with 80 cases and the severe MPP/refractory MPP(SMPP/RMPP)group with 160 cases,and then randomly divided into the control group and the experimental group at a ratio of 1 ∶1,using the random number table method.After screening,subjects entered a treatment period of 5 to 7 days.The control group was treated with azithromycin,while the experimental group was treated with azithromycin plus lienal polypeptide injection .The recovery of lung CT,length of hospital stay,duration of fever,cough score,whether mild cases developed into severe or refractory cases,duration of hormone use,use of intravenous immunoglobulin(IVIG),bronchoscopy treatment,and immune function were observed between the two groups to evaluate the efficacy of lienal polypeptide injection.Adverse events after medication,vital signs,blood routine,urine routine,liver function,myocardial enzymes,renal function,and electrocardiogram were observed to evaluate the safety. Results:A total of 231 subjects have completed the trial in the 7 hospitals,including 118 cases in the experimental group and 113 cases in the control group.Main observation index:the rate of lung CT aggravation in the experimental group was lower than that in the control group(2.6% vs 15.3%, P<0.01),and the difference was statistically significant.Secondary indexes:there were no statistically significant differences in the length of hospital stay,duration of fever,cough score,duration of hormone use,whether IVIG treatment was used,the number of bronchoscopy treatment cases,and immunoglobulin between the two groups(all P>0.05).However,the rate of cases of plastic bronchitis(PB)found under bronchoscopy in the experimental group was lower than that in the control group(0 vs 18.8%, P=0.03),and the difference was statistically significant.Among the mild MPP(72 cases),there were no statistically significant differences in the length of hospital stay,duration of fever,cough score,duration of hormone use,whether IVIG treatment was used,the number of bronchoscopy treatment cases,and the improvement rate of lung CT between the two groups(all P>0.05).However,compared with the control group,the rate of cases developing into SMPP/RMPP in the experimental group was less(24.3% vs 48.6%, P=0.03),and the difference in IgG before and after treatment was small[0.53(-0.04,1.18)g/L vs 1.33(0.48,2.25)g/L, P=0.01].Among the SMPP/RMPP cases(159 cases),the rate of cases of PB found under bronchoscopy in the experimental group was less than that in the control group(0 vs 20%, P=0.04),and the rate of cases with aggravated lung CT in the experimental group was less than that in the control group(1.3% vs 19.5%, P<0.01),and the improvement rate of lung CT in the experimental group was higher than that in the control group(88.8% vs 75.3%, P=0.03),with statistically significant differences.There were no statistically significant differences in the length of hospital stay,duration of fever,cough score,duration of hormone use,whether IVIG treatment was used,the number of bronchoscopy treatment cases,and immunoglobulin between the two groups(all P>0.05).Two cases in the experimental group developed rashes,which improved after the drug was discontinued.There were no serious adverse reactions such as abnormal vital signs like dyspnea and cyanosis due to the use of lienal polypeptide injection.There were no obvious changes in blood routine,liver function,myocardial enzymes,renal function,electrocardiogram,and urine routine values before and after medication compared with the baseline. Conclusion:The combined use of lienal polypeptide injection in the treatment of MPP in children can reduce the probability of the transformation from mild cases to SMPP/RMPP,reduce the rate of aggravation of the image findings,promote the absorption of lung inflammation,reduce the rate of PB found under bronchoscopy,and has good safety.
9.Application and prospect of artificial intelligence in interventional medicine
Ziyu YANG ; Xiyu ZHU ; Juanyang YU ; Dingyi XIAO ; Yaqing BIAN ; Wei HUANG ; Zhiyuan WU ; Xiaoyi DING ; Zhongmin WANG ; Junwei GU
Journal of Interventional Radiology 2025;34(4):441-444
The in-depth research of artificial intelligence in the medical field has greatly improved the workflow and diagnostic ability of diagnostic radiology.This article focuses on artificial intelligence technology in the field of interventional medicine,and enumerates its potential application scenarios,including improving image analysis capabilities to assist diagnosis and predict treatment response.It also describes the challenges that need to be overcome for practical application.Finally,with the continuous development of artificial intelligence in interventional medicine,artificial intelligence will further optimize the channels of interventional medicine and bring revolutionary changes to the clinical practice of interventional medicine.
10.Study on characteristic chromatogram of Chaenomeles sinensis and content determination of 3 flavones
Tianmi ZHU ; Shuhe CHEN ; Jingsong YAN ; Xingui WANG ; Yuqing DUAN ; Xiaoyi YANG
China Pharmacy 2024;35(2):150-154
OBJECTIVE To establish the characteristic chromatogram of Chaenomeles sinensis, determine the contents of rutin, hyperin and quercitrin, and to identify C. sinensis and C. speciosa. METHODS HPLC method was performed on Agilent 5 TC-C18 column, with acetonitrile-0.2% formic acid solution as the mobile phase for gradient elution, at the flow rate of 1.0 mL/min. The column temperature was 30 ℃ . The detection wavelength was 330 nm in characteristic chromatogram and 350 nm in content determination. The characteristic chromatogram of C. sinensis was established and similarity was evaluated by the Similarity Evaluation System for Chromatographic Fingerprint of TCM (2012 edition). Hierarchical cluster analysis of 15 batches of C. sinensis (S1-S15) was performed by using SPSS 23.0 software. The contents of 3 flavones in 15 batches of C. sinensis and 7 batches of C. speciosa (S16-S22) were determined, while their characteristic chromatograms were compared. RESULTS The similarities of the characteristic chromatogram for 15 batches of C. sinensis ranged from 0.783 to 0.969, and 11 characteristic peaks were confirmed. Four constituents were identified as chlorogenic acid, rutin, hyperin and quercitrin. The medicinal materials in 15 batches of C. sinensis could be divided into 2 categories: S5-S8 were one category, and the others belonged to one category. The characteristic chromatogram of C. sinensis was obviously different from C. speciosa. The contents of rutin, hyperin and quercitrin in 15 batches of C. sinensis were 48.99-294.45, 3.49-102.55, 31.98-149.49 μg/g, respectively. The content of rutin in C. speciosa was lower than that in C. sinensis. None of hyperin (except for S20) and quercitrin were detected in C. speciosa. CONCLUSIONS The characteristic chromatogram and the method for content determination of 3 flavones in C. sinensis are established successfully and can be used for the quality control of C. sinensis and its identification from C. speciosa.

Result Analysis
Print
Save
E-mail